These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 35608373)

  • 21. Comparing the efficacy of low-dose vs high-dose cyclophosphamide regimen as induction therapy in the treatment of proliferative lupus nephritis: a single center study.
    Mehra S; Usdadiya JB; Jain VK; Misra DP; Negi VS
    Rheumatol Int; 2018 Apr; 38(4):557-568. PubMed ID: 29450636
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: systematic review and meta-analysis.
    Kamanamool N; McEvoy M; Attia J; Ingsathit A; Ngamjanyaporn P; Thakkinstian A
    Medicine (Baltimore); 2010 Jul; 89(4):227-235. PubMed ID: 20616662
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Moderator's view: The use of calcineurin inhibitors in the treatment of lupus nephritis.
    Kronbichler A; Neumann I; Mayer G
    Nephrol Dial Transplant; 2016 Oct; 31(10):1572-6. PubMed ID: 27591329
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multitarget therapy of mycophenolate mofetil and cyclosporine A for induction treatment of refractory lupus nephritis.
    Jesus D; Rodrigues M; da Silva JAP; Inês L
    Lupus; 2018 Jul; 27(8):1358-1362. PubMed ID: 29448882
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mycophenolate mofetil or cyclophosphamide in indian patients with lupus nephritis: Which is better? A single-center experience.
    Mendonca S; Gupta D; Ali S; Gupta P
    Saudi J Kidney Dis Transpl; 2017; 28(5):1069-1077. PubMed ID: 28937065
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis.
    Basu B; Roy B; Babu BG
    Pediatr Nephrol; 2017 Jun; 32(6):1013-1021. PubMed ID: 28191596
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis.
    Hu W; Liu Z; Chen H; Tang Z; Wang Q; Shen K; Li L
    Chin Med J (Engl); 2002 May; 115(5):705-9. PubMed ID: 12133539
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rituximab use as induction therapy for lupus nephritis: a systematic review.
    Stolyar L; Lahita RG; Panush RS
    Lupus; 2020 Jul; 29(8):892-912. PubMed ID: 32486934
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multitarget therapy versus monotherapy as induction treatment for lupus nephritis: A meta-analysis of randomized controlled trials.
    Lee YH; Song GG
    Lupus; 2022 Oct; 31(12):1468-1476. PubMed ID: 35986446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term outcomes of lupus nephritis treated with regimens based on cyclophosphamide and mycophenolate mofetil.
    Prasad N; Kurian J; Agarwal V; Bhadauria D; Behera M; Yacha M; Kushwaha R; Agrawal V; Jain M; Gupta A
    Lupus; 2020 Jul; 29(8):845-853. PubMed ID: 32437258
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of low-dose cyclophosphamide followed by AZA/MMF treatment in childhood lupus nephritis.
    Baskin E; Ozen S; Cakar N; Bayrakci US; Demirkaya E; Bakkaloglu A
    Pediatr Nephrol; 2010 Jan; 25(1):111-7. PubMed ID: 19727839
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Remission and long-term outcomes of proliferative lupus nephritis: retrospective study of 96 patients from Saudi Arabia.
    Almalki AH; Alrowaie FA; Alhozali HM; Almalki NK; Alsubei AI; Alturki MS; Sadagah LF
    Lupus; 2019 Aug; 28(9):1082-1090. PubMed ID: 31296138
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of high-dose of mycophenolate mofetil compared with cyclophosphamide pulse therapy as induction therapy in Japanese patients with proliferative lupus nephritis.
    Ohkubo N; Iwata S; Nakano K; Miyagawa I; Hanami K; Fukuyo S; Miyazaki Y; Kawabe A; Nakayamada S; Tanaka Y
    Mod Rheumatol; 2022 Oct; 32(6):1077-1085. PubMed ID: 34915579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of disease activity between tacrolimus and mycophenolate mofetil in lupus nephritis: a randomized controlled trial.
    Kamanamool N; Ingsathit A; Rattanasiri S; Ngamjanyaporn P; Kasitanont N; Chawanasuntorapoj R; Pichaiwong W; Anutrakulchai S; Sangthawan P; Ophascharoensuk V; Avihingsanon Y; Sumethkul V
    Lupus; 2018 Apr; 27(4):647-656. PubMed ID: 29105558
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative efficacy and safety of tacrolimus, mycophenolate mofetil, azathioprine, and cyclophosphamide as maintenance therapy for lupus nephritis : A Bayesian network meta-analysis of randomized controlled trials.
    Lee YH; Song GG
    Z Rheumatol; 2017 Dec; 76(10):904-912. PubMed ID: 27638015
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mycophenolate mofetil vs. cyclophosphamide-based induction regimens for lupus nephritis: Outcomes at a tertiary care centre in Lahore, Pakistan.
    Saeed MA; Khan A; Naeem F; Ahmad NM
    J Pak Med Assoc; 2024 May; 74(5):868-873. PubMed ID: 38783432
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the Effectiveness and Safety of Mycophenolate Mofetil and Cyclophosphamide in Lupus Nephritis: Evidence from a Real-World Study.
    Zhang X; Huang H; Gao D; Zhao J; Ji L; Fan Y; Hao Y; Zhang Z
    Rheumatol Ther; 2023 Oct; 10(5):1199-1213. PubMed ID: 37418122
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Mycophenolate Mofetil Versus Intravenous Pulse Cyclophosphamide as Induction Therapy in Proliferative Lupus Nephritis.
    Gadakchi L; Hajialilo M; Nakhjavani MR; Abedi Azar S; Kolahi S; Gojazadeh M; Ebrahimi AA; Malek Mahdavi A; Noshad H; Khabbazi A
    Iran J Kidney Dis; 2018 Oct; 12(5):288-292. PubMed ID: 30367020
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes following mycophenolate mofetil versus cyclophosphamide induction treatment for proliferative juvenile-onset lupus nephritis.
    Smith E; Al-Abadi E; Armon K; Bailey K; Ciurtin C; Davidson J; Gardner-Medwin J; Haslam K; Hawley D; Leahy A; Leone V; McErlane F; Mewar D; Modgil G; Moots R; Pilkington C; Ramanan A; Rangaraj S; Riley P; Sridhar A; Wilkinson N; Beresford MW; Hedrich CM
    Lupus; 2019 Apr; 28(5):613-620. PubMed ID: 30871425
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mycophenolate mofetil as maintenance therapy for proliferative lupus nephritis: a long-term observational prospective study.
    Laskari K; Mavragani CP; Tzioufas AG; Moutsopoulos HM
    Arthritis Res Ther; 2010; 12(6):R208. PubMed ID: 21059275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.